Hudson Bay Capital Management
KYMR icon

Hudson Bay Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Hudson Bay Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,710
Closed -$309K – 1536
2026
Q1 		$309K Buy
+3,710
New +$294K ﹤0.01% 1027
2025
Q4 		– Sell
-23,134
Closed -$1.31M – 1376
2025
Q3 		$1.31M Buy
23,134
+18,134
+363% +$818K ﹤0.01% 817
2025
Q2 		$218K Buy
+5,000
New +$172K ﹤0.01% 1192

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Hudson Bay Capital Management's KYMR Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Kymera Therapeutics (KYMR) in Q2 2026, closing a stake of 3,710 shares — an estimated $309K sold.

Hudson Bay Capital Management first reported a position in KYMR in Q2 2025 and held it in 3 quarters. The position peaked at $1.31M in Q3 2025. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Kymera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 3,710 Kymera Therapeutics shares in Q2 2026, an estimated $309K.
  • Hudson Bay Capital Management first reported a position in Kymera Therapeutics in Q2 2025 and held it in 3 quarters.
  • Hudson Bay Capital Management's Kymera Therapeutics position peaked at $1.31M in Q3 2025.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.